Abstract
Introduction
Infliximab, a chimeric monoclonal antibody to tumour necrosis factor alpha, is administered as an intravenous infusion requiring a costly hospital day case or inpatient admission.
Methods
An audit of all current therapies given by intravenous infusions in an outpatient setting in St Vincent’s University Hospital (SVUH) was undertaken. Furthermore, in conjunction with TCP homecare, we established in a general practise health clinic, the first Irish community infusion centre for the administration of infliximab in August 2006.
Results
All outpatient departments indicated that they would favour a centralized hospital infusion unit. There were no adverse events and the mean global satisfaction improved in the community infliximab infusion pilot programme of seven patients.
Conclusion
This study suggests efficiencies in providing centralized infusion facilities, while the community based infusion of infliximab is feasible and safe in this small cohort and identifies the community infusion unit as a viable and cost efficient alternative for administration of infliximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66(11):1473–1478. doi:10.1136/ard.2007.072447
Manadan AM, James N, Block JA (2007) New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol 19(3):259–264
Boehncke WH, Prinz J, Gottlieb AB (2006) Biologic therapies for psoriasis. A systematic review. J Rheumatol 33(7):1447–1451
Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P (2007) Crohn’s disease: a review of current treatment with a focus on biologics. Drugs 67(17):2511–2537
Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, Dawson R et al (2005) Randomized controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 330:129. doi:10.1136/bmj.38309.447975.EB
Grayson ML, Silvers J, Turnidge J (1995) Home intravenous antibiotic therapy. A safe and effective alternative to inpatient care. Med J Aust 162(5):249–253
Nathwani D, Morrison J, Seaton RA, France AJ, Davey P, Gray K (1999) Out-patient and home-parenteral antibiotic therapy (OHPAT): evaluation of the impact of one year’s experience in Tayside. Health Bull (Edinb) 57(5):332–337
Coyte PC, Dobrow MJ, Broadfield L (2001) Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics 19(8):845–854. doi:10.2165/00019053-200119080-00006
van Eijk Y, Boonen A, Schulpen G, Schrijnemaekers V, Fiolet H, van der Linden S (2006) Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse. Ann Rheum Dis 65:276. doi:10.1136/ard.2005.036566
Condino AA, Fidanza S, Hoffenberg EJ (2005) A home infliximab infusion program. J Pediatr Gastroenterol Nutr 40(1):67–69. doi:10.1097/00005176-200501000-00012
Stuby U, Biesenbach G, Pieringer H (2007) Administration of infliximab in general practitioners’ offices is safe. Clin Rheumatol 26(11):1863–1866. doi:10.1007/s10067-007-0590-5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doran, JP., Alraqi, S., Callanan, I. et al. An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions. Ir J Med Sci 178, 497–501 (2009). https://doi.org/10.1007/s11845-008-0274-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0274-4